wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q26775483-D71BE1AB-6513-4CE3-B249-F705D6A63F03
Q26775483-D71BE1AB-6513-4CE3-B249-F705D6A63F03
BestRank
Statement
http://www.wikidata.org/entity/statement/Q26775483-D71BE1AB-6513-4CE3-B249-F705D6A63F03
c-Met as a Target for Personalized Therapy
P2860
Q26775483-D71BE1AB-6513-4CE3-B249-F705D6A63F03
BestRank
Statement
http://www.wikidata.org/entity/statement/Q26775483-D71BE1AB-6513-4CE3-B249-F705D6A63F03
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
2bfa96542cb7ed6e7cbec6fcde983235a44a3a63
P2860
Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial.